Merck's Crixivan EU Label To Carry Lipodystrophy ADR
Executive Summary
European labeling for Merck's protease inhibitor Crixivan (indinavir) is being updated to include lipodystrophy as an adverse drug reaction, according to the U.K.' s HIV adverse drug reaction program.